Narsoplimab is also in a phase 3 trial regarding safety and efficacy to treat immunogloblulin A (IgA) nephropathy, a chronic kidney disease and it's in a phase 2 trial to treat several conditions affecting kidneys: IgA nephropathy lupus nephritis, when the immune system attacks the kidneys in patients with lupus membranous nephropathy, when small blood cells in the kidneys become damaged and thickened and in complement component 3, when the glomeruli, the small capillary networks that filter the blood in the kidneys, become damaged. The condition, which carries a high mortality factor, is a complication of HSCT that causes damage to small blood vessels inside crucial organs - most often the kidneys and brain. 17 about the Biologics License Application (BLA) regarding narsoplimab (OMS721) to treat hematopoietic stem cell transplantation (HSCT)-associated thrombotic microangiopathy (TA-TMA).
The biotech company said in its second-quarter earnings report that it expects to hear from the Food and Drug Administration (FDA) by Oct. Omeros shareholders are waiting to see what happens this month. Investors tend to get conservative when the market falls, and September was the worst month in a decade, with the Dow Jones Industrial Average, S&P 500, and Nasdaq all showing losses of more than 4%.
However, there were bigger market trends at play that drove the biotech sector down by more than 6% over the month. While that news didn't wow investors by itself, it wasn't that negative, as a lot of biotechs aren't yet profitable.
0 kommentar(er)
